Meningococcal disease
| Meningococcal disease | |
|---|---|
| Other names | invasive meningococcal disease (IMD) |
| Charlotte Cleverley-Bisman, a young survivor of meningococcal disease. Her necrotic arms and legs had to be amputated later. | |
| Specialty | |
| Symptoms | |
| Complications |
|
| Usual onset | Usually 3โ4 days |
| Causes | Neisseria meningitidis spread by respiratory droplets or saliva |
| Risk factors | |
| Diagnostic method | Isolation of N. meningitidis from blood or cerebrospinal fluid by culture or PCR |
| Prevention |
|
| Treatment | |
| Medication | Antibiotics including cephalosporins, penicillins, and rifampin |
| Prognosis | 80% mortality rate if untreated; 4โ20% mortality rate with treatment |
| Frequency | 1.2 million (2012) |
| Deaths | 135,000 (2012) |
Meningococcal disease is a serious, vaccine-preventable infection caused by Neisseria meningitidis, a gram-negative diplococcus bacterium also known as meningococcus. Meningococcal disease presents as life-threatening and rapidly progressive meningitis (infection of the protective membranes surrounding the brain and spinal cord), meningococcal septicemia (infection of the bloodstream), or a combination of both. Initial symptoms are flu-like and generally nonspecific, including fever, headache, neck stiffness, nausea, vomiting, and neurological symptoms including photophobia and confusion. A purple non-blanching rash may also be present. As infection progresses, septic shock eventually leads to gangrene and organ failure. Left untreated, meningococcal disease has an 80% mortality rate. With proper treatment, the mortality rate drops to 4โ20%, with roughly 20% of survivors experiencing long-term complications including brain damage, blindness, deafness, and amputation.
Neisseria meningitidis colonizes the nasopharynx of roughly 10% of the population without symptoms, but meningococcal disease can develop in rare cases when the bacteria enter the bloodstream. Meningococcal disease is transmitted by respiratory droplets or saliva from anyone who carries the bacteria in their respiratory tract, including asymptomatic individuals, although transmission usually requires close or lengthy contact. Symptoms usually begin three to four days after exposure. Almost all cases of meningococcal disease are caused by one of six encapsulated serotypes of N. meningitidis: A, B, C, W, X, and Y. Risk factors for infection include immunodeficiency, especially in cases of complement component deficiencies and low or absent spleen function. Diagnosis is often suspected based on symptoms and confirmed by culture or PCR finding N. meningitidis in the blood or cerebrospinal fluid.
Several vaccines against meningococcal disease have been developed against all six disease-causing serotypes and have significantly reduced the incidence of disease. The United States CDC recommends the vaccine for all adolescents, along with children and adults at increased risk of infection. The World Health Organization recommends mass vaccination in areas with high rates of meningococcal disease. Meningococcal disease is treated with antibiotics; cephalosporins are generally the first-line treatment. In severe cases, additional supportive care may be necessary, and necrotic limbs may require amputation. In rarer cases, atypical presentation of meningococcal disease may occur in the form of pneumonia, septic arthritis, and other infections.
Predominant disease-causing serotypes differ by country and age group, with serotype B accounting for most new cases worldwide. Most cases in the developed world are sporadic, with outbreaks rarely occurring in residential settings such as college campuses. In the United States, incidence is highest among children under 5, young adults, and older adults. In some regions, such as the African meningitis belt, meningococcal disease is endemic and outbreaks are more frequent. In 2012, an estimated 1.2 million cases of meningococcal disease occurred worldwide, resulting in roughly 135,000 deaths.